Ming‐Jie Ding, Hao‐Ran Fang, Jia‐Kai Zhang, Ji‐Hua Shi, Xiao Yu, Pei‐Hao Wen, Zhi‐Hui Wang, Sheng‐Li Cao, Yi Zhang, Xiao‐Yi Shi, Hua‐Peng Zhang, Yu‐Ting He, Bing Yan, Hong‐Wei Tang, Dan‐Feng Guo, Jie Gao, Zhen Liu, Li Zhang, Shui‐Jun Zhang, Xiao‐Jing Zhang, Wen‐Zhi Guo – 3 November 2021
Romain Desert, Xiaodong Ge, Zhuolun Song, Hui Han, Daniel Lantvit, Wei Chen, Sukanta Das, Dipti Athavale, Ioana Abraham‐Enachescu, Chuck Blajszczak, Yu Chen, Orlando Musso, Grace Guzman, Yujin Hoshida, Natalia Nieto – 2 November 2021 – Osteopontin (OPN) expression correlates with tumor progression in many cancers, including hepatocellular carcinoma (HCC); however, its role in the onset of HCC remains unclear. We hypothesized that increased hepatocyte‐derived OPN is a driver of hepatocarcinogenesis.
Jasmine Yee, Joanne M. Carson, Behzad Hajarizadeh, Joshua Hanson, James O’Beirne, David Iser, Phillip Read, Anne Balcomb, Joseph S. Doyle, Jane Davies, Marianne Martinello, Philiipa Marks, Gregory J. Dore, Gail V. Matthews, the REACH‐C Study Group – 1 November 2021 – Australia was one of the first countries with unrestricted access to government subsidized direct‐acting antiviral (DAA) therapy for adults with chronic hepatitis C virus.
Yongliang Yang, David Filipovic, Sudin Bhattacharya – 1 November 2021 – The cytochrome P450 (Cyp) proteins Cyp1A1 and Cyp1A2 are strongly induced in the mouse liver by the potent environmental toxicant 2, 3, 7, 8‐tetrachlorodibenzo‐p‐dioxin (TCDD), acting through the aryl hydrocarbon receptor (AHR). The induction of Cyp1A1 is localized within the centrilobular regions of the mouse liver at low doses of TCDD, progressing to pan‐lobular induction at higher doses.
Selvakumar Malleeswaran, Sivanesan Sivajothi, Mettu Srinivas Reddy – 31 October 2021 – Cirrhosis and liver transplantation (LT) surgery are associated with substantial alterations to the patient’s coagulation status. Accurate monitoring of these changes during LT can help manage bleeding proactively and potentially reduce transfusion requirements.
Silvia Liu, Michael A. Nalesnik, Aatur Singhi, Michelle A. Wood‐Trageser, Parmjeet Randhawa, Bao‐Guo Ren, Abhinav Humar, Peng Liu, Yan‐Ping Yu, George C. Tseng, George Michalopoulos, Jian‐Hua Luo – 31 October 2021 – Hepatocellular carcinoma (HCC) is one of the most lethal human cancers. Liver transplantation has been an effective approach to treat liver cancer. However, significant numbers of patients with HCC experience cancer recurrence, and the selection of suitable candidates for liver transplant remains a challenge.
George Cholankeril, Alsadiq Al‐Hillan, Brandon Tarlow, Daniela Abrams, Jake S. Jacobs, Norma P. Flores, Abbas Rana, Fasiha Kanwal, John A. Goss – 31 October 2021
Jean de Ville de Goyet, Ulrich Baumann, Vincent Karam, René Adam, Silvio Nadalin, Nigel Heaton, Raymond Reding, Sophie Branchereau, Darius Mirza, Jürgen L. Klempnauer, Lutz Fischer, Piotr Kalicinski, Michele Colledan, Manuel Lopez Santamaria, Ruben H. Kleine, Christophe Chardot, Sezai Yilmaz, Murat Kilic, Olivier Boillot, Fabrizio Francesco, Wojciech G. Polak, Henkjan J. Verkade, for the European Liver, Intestine Transplant Association – 31 October 2021
Jan C. DeNofrio, Manisha Verma, Andrzej S. Kosinski, Victor Navarro, Tamar H. Taddei, Michael L. Volk, Marie Bakitas, Kavitha Ramchandran – 30 October 2021 – Palliative care (PC) benefits patients with serious illness including end‐stage liver disease (ESLD). As part of a cluster randomized trial, hepatologists were trained to deliver primary palliative care to patients with ESLD using an online course, Palliative Care Always: Hepatology (PCA:Hep). Here we present a multimethod formative evaluation (feasibility, knowledge acquisition, self‐efficacy, and practice patterns) of PCA:Hep.
Cindy Zhang, Andrew Freistaedter, Carolin Schmelas, Manuel Gunkel, Viet Loan Dao Thi, Dirk Grimm – 30 October 2021 – Hepatitis E virus (HEV) is a major public health problem with limited therapeutic options. Here, we engineered adeno‐associated viral vectors of serotype 6 (AAV6) to express short hairpin RNAs (shRNAs) against HEV transcripts with the prospect of down‐regulating HEV replication in vivo. We designed 20 different shRNAs, targeting the genome of the HEV genotype 3 (GT3) Kernow‐C1 p6 strain, for delivery upon AAV6 transduction.